# Autoliv Inc: financial statements, quarterly

ALV · NYSE · CIK 1034670 · [Consumer discretionary](/sectors/consumer-discretionary.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/alv.md) · [Financials](/companies/alv/financials.md) · [Filings](/companies/alv/filings.md) · [Insiders](/companies/alv/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/alv/financials.md?period=annual).

## Income statement

| Line item | Unit | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [2,751 d](/filings/0001193125-26-058162.md) | [2,615](/filings/0000950170-25-054507.md) | [2,605](/filings/0000950170-25-096766.md) | [2,555](/filings/0001193125-25-242063.md) | [2,616 d](/filings/0001193125-26-058162.md) | [2,578](/filings/0001193125-26-160472.md) | [2,714](/filings/0001193125-26-306974.md) | [2,706](/filings/0001193125-26-429588.md) | [2,817 d](/filings/0001193125-26-058162.md) | [2,753](/filings/0001193125-26-160472.md) | [2,803](/filings/0001193125-26-306974.md) | [2,693](/filings/0001193125-26-429588.md) |
| Cost of revenue | $m | [2,222 d](/filings/0001193125-26-058162.md) | [2,172](/filings/0000950170-25-054507.md) | [2,130](/filings/0000950170-25-096766.md) | [2,095](/filings/0001193125-25-242063.md) | [2,065 d](/filings/0001193125-26-058162.md) | [2,100](/filings/0001193125-26-160472.md) | [2,213](/filings/0001193125-26-306974.md) | [2,184](/filings/0001193125-26-429588.md) | [2,245 d](/filings/0001193125-26-058162.md) | [2,227](/filings/0001193125-26-160472.md) | [2,294](/filings/0001193125-26-306974.md) | [2,197](/filings/0001193125-26-429588.md) |
| Gross profit | $m | [531 d](/filings/0001193125-26-058162.md) | [443](/filings/0000950170-25-054507.md) | [475](/filings/0000950170-25-096766.md) | [459](/filings/0001193125-25-242063.md) | [550 d](/filings/0001193125-26-058162.md) | [478](/filings/0001193125-26-160472.md) | [501](/filings/0001193125-26-306974.md) | [522](/filings/0001193125-26-429588.md) | [572 d](/filings/0001193125-26-058162.md) | [526](/filings/0001193125-26-160472.md) | [509](/filings/0001193125-26-306974.md) | [496](/filings/0001193125-26-429588.md) |
| Research and development | $m | [82.0 d](/filings/0001193125-26-058162.md) | [113](/filings/0000950170-25-054507.md) | [116](/filings/0000950170-25-096766.md) | [96.0](/filings/0001193125-25-242063.md) | [73.0 d](/filings/0001193125-26-058162.md) | [95.0](/filings/0001193125-26-160472.md) | [107](/filings/0001193125-26-306974.md) | [117](/filings/0001193125-26-429588.md) | [94.0 d](/filings/0001193125-26-058162.md) | [120](/filings/0001193125-26-160472.md) | [122](/filings/0001193125-26-306974.md) | [99.0](/filings/0001193125-26-429588.md) |
| Selling, general and administrative | $m | [120 d](/filings/0001193125-26-058162.md) | [132](/filings/0000950170-25-054507.md) | [138](/filings/0000950170-25-096766.md) | [129](/filings/0001193125-25-242063.md) | [131 d](/filings/0001193125-26-058162.md) | [145](/filings/0001193125-26-160472.md) | [145](/filings/0001193125-26-306974.md) | [137](/filings/0001193125-26-429588.md) | [144 d](/filings/0001193125-26-058162.md) | [161](/filings/0001193125-26-160472.md) | [138](/filings/0001193125-26-306974.md) | [138](/filings/0001193125-26-429588.md) |
| Operating income | $m | [237 d](/filings/0001193125-26-058162.md) | [194](/filings/0000950170-25-054507.md) | [206](/filings/0000950170-25-096766.md) | [226](/filings/0001193125-25-242063.md) | [353 d](/filings/0001193125-26-058162.md) | [254](/filings/0001193125-26-160472.md) | [247](/filings/0001193125-26-306974.md) | [267](/filings/0001193125-26-429588.md) | [319 d](/filings/0001193125-26-058162.md) | [237](/filings/0001193125-26-160472.md) | [192](/filings/0001193125-26-306974.md) | [254](/filings/0001193125-26-429588.md) |
| Interest expense | $m | [25.0 d](/filings/0001193125-26-058162.md) | [26.0](/filings/0000950170-25-054507.md) | [28.0](/filings/0000950170-25-096766.md) | [27.0](/filings/0001193125-25-242063.md) | [27.0 d](/filings/0001193125-26-058162.md) | [25.0](/filings/0001193125-26-160472.md) | [27.0](/filings/0001193125-26-306974.md) | [25.0](/filings/0001193125-26-429588.md) | [26.0 d](/filings/0001193125-26-058162.md) | [26.0](/filings/0001193125-26-160472.md) | [26.0](/filings/0001193125-26-306974.md) | [23.0](/filings/0001193125-26-429588.md) |
| Income tax | $m | [(8.0) d](/filings/0001193125-26-058162.md) | [47.0](/filings/0000950170-25-054507.md) | [44.0](/filings/0000950170-25-096766.md) | [58.0](/filings/0001193125-25-242063.md) | [78.0 d](/filings/0001193125-26-058162.md) | [65.0](/filings/0001193125-26-160472.md) | [53.0](/filings/0001193125-26-306974.md) | [65.0](/filings/0001193125-26-429588.md) | [67.0 d](/filings/0001193125-26-058162.md) | [60.0](/filings/0001193125-26-160472.md) | [53.0](/filings/0001193125-26-306974.md) | [75.0](/filings/0001193125-26-429588.md) |
| Net income | $m | [227 d](/filings/0001193125-26-058162.md) | [126](/filings/0000950170-25-054507.md) | [138](/filings/0000950170-25-096766.md) | [138](/filings/0001193125-25-242063.md) | [243 d](/filings/0001193125-26-058162.md) | [167](/filings/0001193125-26-160472.md) | [167](/filings/0001193125-26-306974.md) | [175](/filings/0001193125-26-429588.md) | [226 d](/filings/0001193125-26-058162.md) | [141](/filings/0001193125-26-160472.md) | [100](/filings/0001193125-26-306974.md) | [155](/filings/0001193125-26-429588.md) |
| Diluted EPS | $ per share | not reported | [1.52](/filings/0000950170-25-054507.md) | [1.71](/filings/0000950170-25-096766.md) | [1.74](/filings/0001193125-25-242063.md) | not reported | [2.14](/filings/0001193125-26-160472.md) | [2.16](/filings/0001193125-26-306974.md) | [2.28](/filings/0001193125-26-429588.md) | not reported | [1.88](/filings/0001193125-26-160472.md) | [1.35](/filings/0001193125-26-306974.md) | [2.13](/filings/0001193125-26-429588.md) |
| Basic EPS | $ per share | not reported | [1.53](/filings/0000950170-25-054507.md) | [1.71](/filings/0000950170-25-096766.md) | [1.75](/filings/0001193125-25-242063.md) | not reported | [2.15](/filings/0001193125-26-160472.md) | [2.17](/filings/0001193125-26-306974.md) | [2.29](/filings/0001193125-26-429588.md) | not reported | [1.89](/filings/0001193125-26-160472.md) | [1.35](/filings/0001193125-26-306974.md) | [2.13](/filings/0001193125-26-429588.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [498](/filings/0000950170-25-023852.md) | [569](/filings/0000950170-24-048710.md) | [408](/filings/0000950170-24-084773.md) | [415](/filings/0000950170-24-115455.md) | [330](/filings/0001193125-26-058162.md) | [322](/filings/0000950170-25-054507.md) | [237](/filings/0000950170-25-096766.md) | [225](/filings/0001193125-25-242063.md) | [604](/filings/0001193125-26-429588.md) | [342](/filings/0001193125-26-160472.md) | [377](/filings/0001193125-26-306974.md) | [197](/filings/0001193125-26-429588.md) |
| Current assets | $m | [3,974](/filings/0000950170-25-023852.md) | [4,011](/filings/0000950170-24-048710.md) | [3,703](/filings/0000950170-24-084773.md) | [3,865](/filings/0000950170-24-115455.md) | [3,483](/filings/0001193125-26-058162.md) | [3,699](/filings/0000950170-25-054507.md) | [3,929](/filings/0000950170-25-096766.md) | [3,946](/filings/0001193125-25-242063.md) | [4,101](/filings/0001193125-26-429588.md) | [3,987](/filings/0001193125-26-160472.md) | [4,009](/filings/0001193125-26-306974.md) | [3,951](/filings/0001193125-26-429588.md) |
| Total assets | $m | [8,332](/filings/0000950170-25-023852.md) | [8,324](/filings/0000950170-25-054507.md) | [8,010](/filings/0000950170-25-096766.md) | [8,306](/filings/0001193125-25-242063.md) | [7,804](/filings/0001193125-26-058162.md) | [8,114](/filings/0001193125-26-160472.md) | [8,476](/filings/0001193125-26-306974.md) | [8,463](/filings/0001193125-26-429588.md) | [8,644](/filings/0001193125-26-429588.md) | [8,468](/filings/0001193125-26-160472.md) | [8,497](/filings/0001193125-26-306974.md) | [8,427](/filings/0001193125-26-429588.md) |
| Current liabilities | $m | [4,035](/filings/0000950170-25-023852.md) | [3,658](/filings/0000950170-24-048710.md) | [3,785](/filings/0000950170-24-084773.md) | [4,034](/filings/0000950170-24-115455.md) | [3,633](/filings/0001193125-26-058162.md) | [3,800](/filings/0000950170-25-054507.md) | [4,235](/filings/0000950170-25-096766.md) | [4,141](/filings/0001193125-25-242063.md) | [3,923](/filings/0001193125-26-429588.md) | [3,708](/filings/0001193125-26-160472.md) | [3,897](/filings/0001193125-26-306974.md) | [3,859](/filings/0001193125-26-429588.md) |
| Long-term debt | $m | [1,324](/filings/0000950170-25-023852.md) | [1,830](/filings/0000950170-24-048710.md) | [1,540](/filings/0000950170-24-084773.md) | [1,586](/filings/0000950170-24-115455.md) | [1,522](/filings/0001193125-26-058162.md) | [1,565](/filings/0000950170-25-054507.md) | [1,372](/filings/0000950170-25-096766.md) | [1,374](/filings/0001193125-25-242063.md) | [1,734](/filings/0001193125-26-429588.md) | [1,699](/filings/0001193125-26-160472.md) | [1,688](/filings/0001193125-26-306974.md) | [1,683](/filings/0001193125-26-429588.md) |
| Current portion of debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Short-term borrowings | $m | [538](/filings/0000950170-25-023852.md) | [310](/filings/0000950170-24-048710.md) | [455](/filings/0000950170-24-084773.md) | [624](/filings/0000950170-24-115455.md) | [387](/filings/0001193125-26-058162.md) | [540](/filings/0000950170-25-054507.md) | [679](/filings/0000950170-25-096766.md) | [654](/filings/0001193125-25-242063.md) | [419](/filings/0001193125-26-429588.md) | [393](/filings/0001193125-26-160472.md) | [350](/filings/0001193125-26-306974.md) | [251](/filings/0001193125-26-429588.md) |
| Shareholders' equity | $m | [2,557](/filings/0000950170-25-023852.md) | [2,428](/filings/0000950170-24-048710.md) | [2,298](/filings/0000950170-24-084773.md) | [2,288](/filings/0000950170-24-115455.md) | [2,276](/filings/0001193125-26-058162.md) | [2,351](/filings/0000950170-25-054507.md) | [2,469](/filings/0000950170-25-096766.md) | [2,549](/filings/0001193125-25-242063.md) | [2,572](/filings/0001193125-26-429588.md) | [2,634](/filings/0001193125-26-160472.md) | [2,490](/filings/0001193125-26-306974.md) | [2,459](/filings/0001193125-26-429588.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Current portion of debt: not reported
- Short-term borrowings: us-gaap:ShortTermBorrowings
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [447 d](/filings/0001193125-26-058162.md) | [122](/filings/0000950170-25-054507.md) | [340 d](/filings/0000950170-25-096766.md) | [177 d](/filings/0001193125-25-242063.md) | [420 d](/filings/0001193125-26-058162.md) | [77.0](/filings/0001193125-26-160472.md) | [278 d](/filings/0001193125-26-306974.md) | [258 d](/filings/0001193125-26-429588.md) | [544 d](/filings/0001193125-26-058162.md) | [(76.0)](/filings/0001193125-26-160472.md) | [435 d](/filings/0001193125-26-306974.md) | [239 d](/filings/0001193125-26-429588.md) |
| Capital expenditure | $m | [153 d](/filings/0001193125-26-058162.md) | [140](/filings/0000950170-25-054507.md) | [154](/filings/0000950170-25-096766.md) | [146](/filings/0001193125-25-242063.md) | [139 d](/filings/0001193125-26-058162.md) | [102](/filings/0001193125-26-160472.md) | [115](/filings/0001193125-26-306974.md) | [106](/filings/0001193125-26-429588.md) | [118 d](/filings/0001193125-26-058162.md) | [85.0](/filings/0001193125-26-160472.md) | [95.0](/filings/0001193125-26-306974.md) | [115](/filings/0001193125-26-429588.md) |
| Dividends paid | $m | [56.0 d](/filings/0001193125-26-058162.md) | [56.0](/filings/0000950170-25-054507.md) | [55.0 d](/filings/0000950170-25-096766.md) | [53.0 d](/filings/0001193125-25-242063.md) | [55.0 d](/filings/0001193125-26-058162.md) | [54.0](/filings/0001193125-26-160472.md) | [54.0 d](/filings/0001193125-26-306974.md) | [65.0 d](/filings/0001193125-26-429588.md) | [65.0 d](/filings/0001193125-26-058162.md) | [65.0](/filings/0001193125-26-160472.md) | [65.0 d](/filings/0001193125-26-306974.md) | [62.0 d](/filings/0001193125-26-429588.md) |
| Share repurchases | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Dividends paid: us-gaap:PaymentsOfDividendsCommonStock
- Share repurchases: not reported

## Shares

| Line item | Unit | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [86.3](/filings/0000950170-24-048710.md) | [85.8](/filings/0000950170-24-084773.md) | [85.0](/filings/0000950170-24-115455.md) | [83.0](/filings/0000950170-25-054507.md) | [81.1](/filings/0000950170-25-096766.md) | [79.3](/filings/0001193125-25-242063.md) | [77.9](/filings/0001193125-26-160472.md) | [77.3](/filings/0001193125-26-306974.md) | [76.7](/filings/0001193125-26-429588.md) | [75.1](/filings/0001193125-26-160472.md) | [74.2](/filings/0001193125-26-306974.md) | [72.9](/filings/0001193125-26-429588.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 72,006,695 at 2026-10-16, from the cover of the [10-Q filed 2026-10-23](/filings/0001193125-26-429588.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:30 ET. No prices; not investment advice.